News

Hospitals Selling Fast Food: A Contradiction In The Fight Against NCDs
Hospitals paradoxically house fast food outlets, raising health concerns. A U.S. poll shows most oppose such sales; India too ...
US FDA Grants Orphan Drug Status To Sanofi’s GPRC5D-Targeting Monoclonal Antibody For Multiple Myeloma
FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...
Pharmabiz4d
US FDA grants orphan drug designation to Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns to treat multiple myeloma
US FDA grants orphan drug designation to Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns to treat multiple myeloma: Paris Friday, August 1, 2025, 09:00 Hrs [IST] The US ...
CURE4d
FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...
Targeted Oncology4d
Novel GPRC5D mAB Receives FDA Orphan Drug Designation in R/R Myeloma
Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...
Oncology Nursing News6d
Best Practices for Monitoring Response to Talquetamab and Optimizing Dosing
Panelists discuss that talquetamab dose modifications are guided primarily by patient symptoms and adverse effects, with ...
PharmiWeb6d
Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...
Medical Dialogues6d
Sanofi earns orphan drug designation from USFDA for multiple myeloma drug
Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for SAR446523, an ...